Copyright © 2021. Inderes Oyj. All rights reserved.
Käyttäjätili

Hei anonyymi!

Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.

Luo tili

Onko sinulla jo Inderes-tili?

Cantargia

Analyytikko

Sisäpiirin kaupat

Nettovaikuttavuus

Tiedotteet
30.8.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported publication of preclinical results demonstrating that Cantargia's lead candidate, the IL1RAP-binding antibody nadunolimab (CAN04), shows synergistic anti-tumor efficacy with chemotherapy through a mechanism likely to be highly relevant in the clinical situation. The effect is dependent on the unique capability of nadunolimab to simultaneously block both the alpha and beta forms of interleukin-1 (IL-1).

Tiedotteet
30.8.
2022

Cantargia AB's ("Cantargia") half year report for the period January until June 2022 is now available on the company's web page www.cantargia.com/en/investors/financial-reports.

Tiedotteet
17.8.
2022

Cantargia AB will publish the company's report for the second quarter for 2022 on Tuesday, August 30, 2022, at 08:30 a.m. CET.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 30, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the second quarter 2022, followed by a Q&A-session.

Tiedotteet
12.8.
2022

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Tiedotteet
25.7.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data from a collaboration with Johns Hopkins University School of Medicine demonstrating efficacy of CAN10 in a viral myocarditis model. The results highlight the potential of CAN10 in the treatment of this common form of myocarditis ahead of planned clinical trials. The data will be presented in a poster session at one of the world's largest meetings on innovations in cardiac health, the Basic Cardiovascular Sciences (BCVS) Scientific Sessions 2022, being held in Chicago, July 25-28, 2022.

Tiedotteet
22.7.
2022

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Tiedotteet
21.7.
2022
Cantargia's extraordinary general meeting on 21 July 2022 resolved in accordance with the following:
  • To, in accordance with the board's proposal, amend section 1 of the company's articles of association, whereby the word "firma" is replaced with "företagsnamn", and, in order to adapt the articles of association in accordance with the board's issue resolution below, amend sections 4 and 5 of the company's articles of association, whereby the limits for the company's share capital are changed to not less than SEK 5,000,000 and not more than SEK 20,000,000 and the limit for t

Tiedotteet
21.7.
2022

Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for US patent application 17/559,227. This application describes composition of matter for the anti-inflammatory IL1RAP-binding antibody CAN10, which Cantargia plans to bring to phase I clinical development early 2023.

Muut analyysit
18.7.
2022

Redeye updates its valuation of Cantargia after the terms of its rights issue have been announced.

Tiedotteet
18.7.
2022

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND WHAT IS REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE.

Cantargia